Key Points
- Insider Markus Puhlmann bought 35,000 shares at an average $0.84 each, worth $29,400, increasing his stake by 24.38% to 178,542 shares. He had also purchased 6,000 shares the previous day.
- Perspective Therapeutics reported a quarterly loss of $0.27 per share, wider than the $0.24 expected, while revenue of $0.02 million fell short of the $0.06 million forecast.
- Analysts maintain a “Moderate Buy” consensus, with an average price target of $10.10; nine analysts rate the stock Buy and two rate it Hold.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) insider Markus Puhlmann bought 35,000 shares of the company's stock in a transaction on Thursday, November 12th. The stock was purchased at an average price of $0.84 per share, with a total value of $29,400.00. Following the completion of the transaction, the insider directly owned 178,542 shares of the company's stock, valued at approximately $149,975.28. The trade was a 24.38% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Markus Puhlmann also recently made the following trade(s):
- On Wednesday, November 11th, Markus Puhlmann purchased 6,000 shares of Perspective Therapeutics stock. The shares were purchased at an average cost of $0.83 per share, for a total transaction of $4,980.00.
Perspective Therapeutics Stock Performance
Shares of CATX stock traded up $0.10 during mid-day trading on Friday, reaching $0.94. 3,183,208 shares of the stock traded hands, compared to its average volume of 4,328,272. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.61 and a current ratio of 5.18. The stock's fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $3.44. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. Equities analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.
Key Headlines Impacting Perspective Therapeutics
Investors following CATX have been watching these headlines:
- Positive Sentiment: CEO Johan Spoor bought 47,000 shares at an average price of $0.81, increasing his holdings by 79%. Insider Markus Puhlmann also bought 41,000 shares across two transactions at average prices of $0.83 and $0.84. These open-market purchases may signal insiders’ confidence in the company. Insider purchase report
- Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates
- Negative Sentiment: The company’s latest reported quarter missed expectations: its loss of $0.27 per share was wider than the $0.24 consensus estimate, while revenue of $0.02 million fell short of the $0.06 million forecast. This weak operating performance may weigh on sentiment. CATX earnings information
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on CATX shares. William Blair initiated coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They set an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and issued a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. BMO Capital Markets reissued an "outperform" rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. BTIG Research restated a "buy" rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, Piper Sandler lowered their target price on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.10.
Get Our Latest Research Report on CATX
Institutional Investors Weigh In On Perspective Therapeutics
A number of institutional investors have recently modified their holdings of CATX. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics in the 1st quarter valued at $26,424,000. Avidity Partners Management LP raised its stake in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock worth $25,228,000 after buying an additional 2,839,266 shares during the last quarter. Affinity Asset Advisors LLC lifted its holdings in Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company's stock valued at $13,196,000 after buying an additional 2,864,582 shares during the period. Spruce Street Capital LP acquired a new position in Perspective Therapeutics in the first quarter valued at $10,955,000. Finally, Nantahala Capital Management LLC lifted its holdings in Perspective Therapeutics by 7.2% in the third quarter. Nantahala Capital Management LLC now owns 2,492,642 shares of the company's stock valued at $6,855,000 after buying an additional 167,192 shares during the period. 54.66% of the stock is owned by institutional investors.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
